TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial
1. 系统已在2025-11-07 15:40:06对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
Y Zhang, Q Yin, B Zhao, F Liu, S Li, J Cai, X Fang…
Med
cell.com
Background Dysregulation of bromodomain and extra-terminal domain (BET) proteins causes aberrant acetylation of histones, triggering oncogene expression in malignancies. TQB3617 is an orally administered BET inhibitor that competitively binds to bromodomains and inhibits their activities. Methods This phase 1 trial assessed the safety, pharmacokinetics, and efficacy of TQB3617 in patients with relapsed or refractory lymphomas. The primary endpoints were the safety, dose-limiting toxicity (DLT), and the …
